Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bcl-xL is an oncogenic driver in colorectal cancer.

Cell death & disease - 18 Aug 2016

Scherr Anna-Lena, Gdynia Georg, Salou Mariam, Radhakrishnan Praveen, Duglova Katarina, Heller Anette, Keim Sophia, Kautz Nicole, Jassowicz Adam, Elssner Christin, He You-Wen, Jaeger Dirk, Heikenwalder Mathias, Schneider Martin, Weber Achim, Roth Wilfried, Schulze-Bergkamen Henning, Koehler Bruno Christian

Abstract excerpt

Colorectal cancer (CRC) is the second most common malignant neoplasia in women and men worldwide. The B-cell lymphoma 2 (Bcl-2) protein family is mainly known for its pivotal role in the regulation of the mitochondrial death pathway. Anti-apoptotic Bcl-2 proteins may provide survival benefits and induce therapy resistance in cancer cells. Among anti-apoptotic Bcl-2 proteins, we found solely Bcl-xL strongly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-X Protein
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinogenesis

Share to Enterocytes

Share to Lymphocytes, Tumor-Infiltrating

Share to Nitrophenols

Share to Piperazines

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 27537525
DOI: 10.1038/cddis.2016.233
PMCID: PMC5108319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bcl-xL is an oncogenic driver in colorectal cancer.PMID 27537525Read ↗

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerSemantic proximity Read ↗

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancerSemantic proximity Read ↗

Navigating the interplay between BCL-2 family proteins, apoptosis, and autophagy in colorectal cancerSemantic proximity Read ↗

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.Semantic proximity Read ↗

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.Semantic proximity Read ↗

BCL-xL, a Mitochondrial Protein Involved in Successful Aging: From C. elegans to Human CentenariansSemantic proximity Read ↗

Bcl-xL promotes metastasis independent of its anti-apoptotic activitySemantic proximity Read ↗

Colon cancer: genomics and apoptotic eventsSemantic proximity Read ↗

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Semantic proximity Read ↗

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity Read ↗

Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinomaSemantic proximity Read ↗

BCL-2 system analysis identifies high-risk colorectal cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.